---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-017770"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:37:57.484518+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics secures $25M equity line with Arena; MD Anderson fund requests additional data before grant

## Summary
- Enters purchase agreement with Arena for up to $25M of common stock; shares priced at 90% of Market Price.
- Max advance per notice is lesser of 60% avg daily value traded (or 30% if after 8:30 ET) and $20M/$15M cap.
- Commitment fee shares equal 500,000 divided by avg VWAP over 5 days pre-ELOC reg effectiveness.
- MD Anderson's Cancer Focus Fund requested additional technical data; company expects to reapply short term, funding not assured.
- Shares issued under Section 4(a)(2)/Reg D exemption; 4.99% ownership limitation applies.

## SEC filing metadata
- accession: 0001213900-24-017770
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/0001213900-24-017770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/ea0200582-8k_cerothera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-017770
- JSON: https://secwatch.observer/filing/0001213900-24-017770.json
- Plain text: https://secwatch.observer/filing/0001213900-24-017770.txt

## Key facts
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Purchase Agreement with Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13 valued at up to $25 million (effective 2024-02-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13
  - Value: up to $25 million
  - Effective: 2024-02-23
  source text: On February 23, 2024, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), entered into a purchase agreement (the “Purchase Agreement ”) with Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13 (“ Arena ”), pursuant to which Arena has committed to purchase up to $25 million (the “ Commitment Amount ”) of the Company’s shares of common stock, par value $0.0001 per share (the “ Common Stock ”), subject to the satisfaction of the conditions in the Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/0001213900-24-017770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.